Showing results (411-420 of 867) with videos related to
Sort By:
Pageof 87
Clinical Toxicology (Philadelphia, Pa.)|May 26, 2016
Idarucizumab for dabigatran overdoseMarijke Peetermans, Charles Pollack, Paul Reilly, et al.The Journal of Biological Chemistry|August 17, 2014
Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrinPaul Y Kim, Trang T Vu, Beverly A Leslie, et al.Thrombosis Research|June 29, 2016
An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgeryBengt I Eriksson, Zsolt Mikuska, Martin Feuring, et al.Journal of Lipid Research|August 12, 2010
Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian populationIlaria Guella, Rosanna Asselta, Diego Ardissino, et al.Thrombosis Research|December 2, 2019
Procoagulant imbalance in preterm neonates detected by thrombin generation proceduresArmando Tripodi, Genny Raffaeli, Erica Scalambrino, et al.Thrombosis and Haemostasis|January 9, 2015
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) projectKathelijn Fischer, Riita Lassila, Flora Peyvandi, et al.Health Services Management Research|February 14, 2024
Design organization and clinical processes around patient characteristics: Evidence from a multiple case study of HemophiliaStefano Villa, Raimondo De Cristofaro, Giovanni Di Minno, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|October 11, 2023
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapyAna Boban, Fariba Baghaei, Fijnvandraat Karin, et al.British Journal of Haematology|December 14, 2020
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia AFlora Peyvandi, Syna Miri, Paolo Bucciarelli, et al.BMJ Open|June 2, 2019
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE studyJohannes Oldenburg, Charles R M Hay, Víctor Jiménez-Yuste, et al.Pageof 87